Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its senior leadership team will present at the prestigious Jefferies London Healthcare Conference.Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will deliver a corporate overview highlighting the Company’s...
Nasdaq GlobeNewswire
13/11/2025
Avicenna.AI Launches AVI: A Seamless Platform For Medical Imaging AI
Fully automatic and invisible to end users, AVI integrates directly with PACS and RIS without requiring additional viewers, worklists, or changes to clinical workflows. Clinicians stay within the tools they already use, IT teams benefit from simplified deployment, and finance leaders gain lower total cost of ownership through reduced maintenance and support requirements. Fully automatic and invisible to end users, AVI integrates directly with PACS and RIS without requiring additional viewers,...
PR Newswire
13/11/2025
From Protection to Personalization: Unlock Your Shine This Black Friday with…
Sometimes it takes a moment of darkness to understand the true value of light. On a quiet Texas highway, a father and daughter were stranded after a late-night accident — their car stalled, their phones dying, and the road silent. From the glove box came an Olight. Its steady beam cut through the night, a quiet promise of safety until help arrived. Sometimes it takes a moment of darkness to understand the true value of light. On a quietTexashighway, a father and daughter were stranded after...
PR Newswire
13/11/2025
Matisse Pharmaceuticals successfully completes study with prolonged infusion of…
th, 2025.Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced top line results from its phase 1 study evaluating the safety, tolerability & pharmacokinetics of a 120-hour intravenous (IV) continuous infusion with its lead compound M6229. The study met its primary objectives, showing favorable safety and tolerability in healthy volunteers. This study also confirmed that M6229, shows a predictable...
Nasdaq GlobeNewswire
13/11/2025
Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot…
STRASBOURG, France, MONTREAL and BOSTON, Nov. 13, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced the appointment of Jean-Marie Cuillerot, M.D., as Chief Medical Officer (CMO). STRASBOURG, France,MONTREALandBOSTON , Nov. 13, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing…
PR Newswire
13/11/2025
icotec Receives FDA Clearance for the CMORE® CT System, Expanding its…
BlackArmor® Engineered Carbon/PEEK is a combination composite material with continuous, high strength carbon-fibers and PEEK, manufactured in a process developed by icotec. The result is an implant component with an interwoven 3D fiber architecture. It is also radiolucent in all diagnostic imaging modes (MRI, CT, and X-ray). BlackArmor ®Engineered Carbon/PEEK is a combination composite material with continuous, high strength carbon-fibers and PEEK, manufactured in a process developed by…
PR Newswire
13/11/2025
Shedding light on the disease: Roma Tor Vergata lights up for World Diabetes Day…
The University of Roma Tor Vergata is joining the global awareness campaign to raise awareness and understanding of diabetes and highlight the importance of prevention and early diagnosis. The façade of the Rectorate is illuminated with the official logo of World Diabetes Day, a blue circle, a symbolic gesture organised by Davide Lauro, Professor of Endocrinology, together with Marco Re, engineer, Professor of Digital Electronics and delegate of the Rector for the planning and management of the…
PR Newswire
13/11/2025
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and…
Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinic Numab Therapeutics AG(“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, and Kaken Pharmaceutical Co., Ltd. (“Kaken”), an R&D driven pharmaceutical company in Japan, today announced a strategic licensing and co-development agreement for NM81, a potential first-in-class multispecific...
Nasdaq GlobeNewswire
13/11/2025
Hitachi Solutions Recognised as the Winner of 2025 Microsoft Government Partner…
Hitachi Solutions ongoing collaborations include transformation programmes with the Department of Health and Social Care (DHSC), supporting data-driven decision-making and operational efficiency; the Environment Agency, enabling better environmental management through modern cloud solutions; and Warwickshire County Council, empowering local services through a citizen-centric digital transformation journey. These partnerships exemplify Hitachi Solutions continued commitment to delivering…
PR Newswire
13/11/2025
Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD…
Dr Miguel Forte, MD, PhD, newly appointed Non-Executive Director of Blue Cell Therapeutics, said: "Blue Cell Therapeutics has a clear vision of how to develop allogeneic stem cell treatments to address significant unmet medical needs, which are not only clinically effective, but can also be manufactured at scale. I believe my clinical, regulatory and managerial experience will complement and strengthen the Company's board, and help Blue Cell as it progresses and seeks to commercialise its…
PR Newswire
13/11/2025
ADNOC Gas Delivers Best-Ever Q3 Results, Demonstrating Resilience and Growth in…
Q3 2025 saw ADNOC Gas' domestic gas business deliver record results, with EBITDA rising to $914 million, up 26% year-on-year. The strength of the UAE economy, which the IMF predicted will grow by 4.8% in 2025 and 5% in 2026, was the primary driver of a 4% increase in domestic gas sales volumes for the first nine months. That is coupled with improved underlying margins following successful structural improvements from contract renegotiations. Q3 2025 saw ADNOC Gas' domestic gas business…
PR Newswire
13/11/2025
Large health system in southeast US adopts Sectra's cloud service across 11…
As Sectra One Cloud is a fully managed cloud solution, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the healthcare system's IT teams. The solution can also be scaled to accommodate growth as volumes increase and expansion into other imaging specialties. As Sectra One Cloud is a fully managed cloud solution, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the healthcare system's IT teams...
PR Newswire
13/11/2025
KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in…
Smart POCT Solutions for Pet Health Smart POCT Solutions for Pet Health 4-in-1 Integration:Biochemistry, Electrolytes, Coagulation, and Immunofluorescence testing combined in one compact platform. Enables veterinarians to perform multi-type tests on one device. One-Step Operation:Simplified workflow delivers results within10 minutes. Broad Test Menu:Covers over90% of routine pet diagnostics Animal-friendly Design:Requires no more than100 μLof sample, ensuring...
PR Newswire
13/11/2025
IMU Biosciences announces formation of Scientific Advisory Board
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and geneticsLondon, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the formation of its Scientific Advisory Board (SAB).Professor Paresh Vyas, Professor Bali Pulendran, Professor Adrian Hayday and Dr Peter Goodfellow, four leading...
Nasdaq GlobeNewswire
13/11/2025
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups…
Despite representing half the global population, women remain underrepresented in clinical research and healthcare investment, with women's health accounting for just 15% of venture capital and 5% of global healthcare R&D funding. Rediscovering Women's Health highlights organizations addressing these gaps through inclusive research, novel therapies and a deeper understanding of female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS) and endometriosis, factors…
PR Newswire
13/11/2025
Inventiva announces temporary trading halt of its ordinary shares on Euronext…
Daix (France), New York City (New York, United States), November 13, 2025 –Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), announced today that trading of its ordinary shares on the regulated market of Euronext Paris (" Euronext Paris ") will be temporarily…
Nasdaq GlobeNewswire
13/11/2025
Enterome to present positive interim Phase 2 data for lead OncoMimics™…
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatmentAll six patients responded positively to the combination Overall response data in cohort 2 confirm EO2463 monotherapy produces marked efficacy in patients in watch-and-wait settingRegistrational Phase 3 trial could start in 2026 in the watch-and-wait settingParis, France – 13 NOVEMBER 2025 (08:30 CET)Enterome, a clinical-stage company...
Nasdaq GlobeNewswire
13/11/2025
Interim Report for the period July - September 2025: BioArctic
Events during the third quarter 2025 Events during the third quarter 2025 Events after the end of the third quarter Financial summary July –September 2025 Comments from the CEO "Our collaboration with Novartis marks an exciting new chapter for BioArctic" Our journey into a new era and the work to meet our long-term ambitions continues, with several important milestones reached during the quarter. The progress made underscores our strong commitment to delivering...
PR Newswire
13/11/2025
Bioretec Ltd's business review January-September 2025: Strengthening commercial…
July–September 2025 in brief July–September 2025 in brief January–September 2025 in brief Key figures Key events during July–September 2025 CEOSarah van Hellenberg Hubar-Fisher'scomments: Strengthening commercial foundations and strategy design "Almost six months have passed since I assumed my position as Bioretec's CEO. While I remain very enthusiastic about Bioretec's next phase of growth and the opportunity to lead us there, it has become increasingly evident...
PR Newswire
13/11/2025
THERANEXUS : THX Pharma announces the strong success of its approximately EUR 8…
Capital increase of €7.8 million through the issuance of 4,356,804 new shares at a unit price of €1.80 The transaction received strong support from existing shareholders, whose demand on irreducible and reducible basis, under the preferential subscription rights amounted to 1,742,660 shares Lyon, France – November 13, 2025, 8am CEST – THX Pharma…
Actusnews Wire
13/11/2025
T-Therapeutics announces Series A extension to $91 million to advance…
$32 million new equity injection adds to previously announced $59 millionNew investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England– T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing,...
Nasdaq GlobeNewswire
13/11/2025
Robert Lewandowski Named Global Brand Ambassador for KSM-66 Ashwagandha
The partnership pairs Lewandowski's two-decade career at football's elite level with KSM-66 Ashwagandha's commitment to 4000 year old Ayurvedic tradition of root-only extraction. His consistency across leagues and clubs, from Borussia Dortmund to Bayern Munich to FC Barcelona, mirrors the quality standards that define KSM-66's manufacturing approach. Manufactured by Ixoreal Biomed, KSM-66 Ashwagandha is trusted as a star ingredient in products of over 4,500 brands worldwide. The partnership...
PR Newswire
13/11/2025
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026.Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving...
Nasdaq GlobeNewswire
13/11/2025
WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical…
Key Takeaways from the WRN Inhibitors Market Report Key Takeaways from the WRN Inhibitors Market Report Discover which indication is expected to grab the major WRN inhibitors market share @WRN Inhibitors Market Report Key Factors Driving the WRN Inhibitors Market Synthetic Lethality Targeting in MSI Cancers WRN inhibitors exploit synthetic lethality by targeting the Werner syndrome helicase (WRN), critical for DNA repair in MSI-H tumors. Tumors with high microsatellite...
PR Newswire
12/11/2025
Altri Comunicati
